Sleeve gastrectomy – a popular bariatric method to treat severe obesity and type 2 diabetes

Česká verzia

Authors: M. Kasalický ^1,2; E. Koblihová ¹; J. Pažin ¹
Authors place of work: Chirurgická klinika 2. LF UK a ÚVN – VFN Praha ¹; Fakulta zdravotníctva a sociálnej práce, Trnavská univerzita v Trnave ²
Published in the journal: Gastroent Hepatol 2018; 72(2): 158-163
Category: Bariatrie: přehledová práce
doi: https://doi.org/10.14735/amgh2018158

Summary

Introduction:
Bariatric and metabolic surgeries are safe and effective methods to treat severe obesity and type 2 diabetes mellitus in morbidly obese patients, resp. Morbidly obese patients have been treated using sleeve gastrectomy (SG) as a single bariatric/metabolic (B/M) procedure since 2003 in other countries and since 2006 in the Czech Republic. Laparoscopic sleeve gastrectomy (LSG) is an effective and feasible B/M procedure with a low rate of complications. This article concerns the use of SG as a bariatric method.

Method:
The main principle of SG is vertical resection of the greater curvature of the stomach. SG is a restrictive method with neurohumoral effects and is usually performed via a laparoscopic minimally invasive approach.

Conclusion:
LSG is a safe bariatric procedure with good long-term results in terms of weight loss and improvement of metabolic co-morbidities as well a low rate of complications, which can be managed laparoscopically. SG is currently the most widely used B/M procedure in the Czech Republic and most other countries.

Key words:
bariatric surgery – sleeve gastrectomy – morbid obesity – diabetes mellitus

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
19. 12. 2017

Accepted:
20. 1. 2018

Zdroje

1. Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol 2015; 11 (8): 465–477. doi: 10.1038/nrendo.2015.84.

2. Li F, Sheng Ch, Song K et al. Preventative sleeve gastrectomy contributes to maintaining β cell function in db/db diabetic mouse. Obes Surg 2016; 26 (10): 2402–2410. doi: 10.1007/s11695-016-2112-5.

3. Angrisani L. Bariatric surgery worldwide 2014. Obes Surg 2015; 25 (10): 1822–1832. doi: 10.1007/s11695-015-1657-z.

4. Kasalický M. Česká bariatrie v roce 2010. Rozhl Chir 2011; 90 (4): 222–225.

5. Gagner M, Hutchinson C, Rosenthal R. Fifth International Consensus Conference: current status of sleeve gastrectomy. Surg Obes Relat Dis 2016; 12 (4): 750–756. doi: 10.1016/j.soard.2016. 01.022.

6. Kasalicky M, Michalsky D, Housova J et al. Laparoscopic sleeve gastrectomy without an over-sewing of the staple line. Obes Surg 2008; 18 (10): 1257−1262. doi: 10.1007/s11695-008-9635-3.

7. Switzer NJ, Prasad S, Debru E et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review of long-term outcomes. Obes Surg 2016; 26 (7): 1616–1621. doi: 10.1007/ s11695-016-2188-y.

8. Kasalický M. Tubulizace žaludku chirurgická léčba obezity. Praha: Triton 2007.

9. Fried M, Gryga A, Herlesová J et al. Obecné indikace a kontraindikace k bariatrii. Rozhl Chir 2013; 92 (1): 41–44.

10. Fried M, Hainer V, Basdevand A et al. Interdisciplinary European guidelines for surgery of severe (morbid) obesity. Obes Surg 2007; 17 (2): 260–270.

11. Alvarenga ES, Lo Menzo E, Szomstein S et al. Safety and efficacy of 1020 consecutive laparoscopic sleeve gastrectomies performed as a primary treatment modality for morbid obesity. A single-center experience from the metabolic and bariatric surgical accreditation quality and improvement program. Surg Endosc 2016; 30 (7): 2673–2678. doi: 10.1007/s00464-015-4548-4.

12. Kasalický M, Bařinka A, Čierny M et al. 10 let sleeve gastrectomy – tubulizace žaludku v České republice z hlediska operačního výkonu. Rozhl Chir 2016; 95 (12): 425–431.

13. Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis 2009; 5 (4): 469–475. doi: 10.1016/j.soard.2009.05.011.

14. Gill RS, Birch DW, Shi X et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis 2010; 6 (6): 707–713. doi: 10.1016/j.soard.2010.07.011.

15. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292 (14): 1724–1737.

16. Puzziferri N, Roshek 3rd TB, Mayo HG et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312 (9): 934–942. doi: 10.1001/jama.2014.10706.

17. Li J, Lai D, Wu D. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy to treat morbid obesity-related comorbidities: a systematic review and meta-analysis. Obes Surg 2016; 26 (2): 429–442. doi: 10.1007/s11695-015-1996-9.

18. Schauer PR, Bhatt DL, Kirwan JP et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med 2017; 376 (7): 641–651. doi: 10.1056/NEJMoa1600 869.

19. Bohdjalian A, Langer FB, Shakeri-Leidenmühler S et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg 2010; 20 (5): 535–540. doi: 10.1007/s11695-009-00 66-6.

20. Wang GF, Yan YX, Xu N et al. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg 2015; 25 (2): 199–208. doi: 10.1007/ s11695-014-1391-y.